Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 5/20 | 0.58 |
| ▸ | PLAU | P00749 | 2/20 | 0.58 |
| ▸ | BACE1 | P56817 | 1/20 | 0.53 |
| ▸ | MCHR1 | Q99705 | 12/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29957732 | 0.78 | METAP2 (0.60) | — | |
| SCHEMBL14988789 | 0.78 | METAP2 (0.60) | — | |
| SCHEMBL29955883 | 0.78 | METAP2 (0.41) | NCF1PLAU | |
| SCHEMBL18341004 | 0.74 | CLK1 (0.41) | — | |
| SCHEMBL3141987 | 0.74 | MTNR1A (0.47) | MCHR1 | |
| SCHEMBL7048517 | 0.74 | NCF1 (0.59) | NCF1PLAUBACE1MCHR1 | |
| SCHEMBL361523 | 0.74 | NCF1 (1.00) | NCF1PLAUBACE1MCHR1 | |
| SCHEMBL30634567 | 0.73 | MCHR1 (0.62) | NCF1PLAUMCHR1 | |
| SCHEMBL17268386 | 0.73 | KDM4E (0.45) | — | |
| SCHEMBL21975961 | 0.73 | NCF1 (0.63) | NCF1PLAUBACE1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114853813-A | Ligand, preparation method and application thereof | 万华化学集团股份有限公司 | 2022-08-05 | — | — | CN | claimed |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | GENENTECH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| EP-4526309-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | Genentech, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| CN-119365467-A | Aza-tetraepoxy aza compounds and uses thereof | 基因泰克公司 | 2025-01-24 | — | — | CN | disclosed |
| US-20240368186-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2024-11-07 | — | — | US | disclosed |
| US-20240025919-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025919-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025919-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2023225302-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-10221163-B2 | Metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20180244656-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-08-30 | — | — | US | disclosed |
| US-20180179190-A1 | METALLO-BETA-LACTAMASE INHIBITORS | Marck Sharp & Dohme Corp. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20180179190-A1 | METALLO-BETA-LACTAMASE INHIBITORS | Marck Sharp & Dohme Corp. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20180179190-A1 | METALLO-BETA-LACTAMASE INHIBITORS | Marck Sharp & Dohme Corp. (US) | 2018-06-28 | — | — | US | disclosed |
| EP-3313832-A1 | 3-TETRAZOLYL-BENZENE-1,2-DISULFONAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-05-02 | — | — | EP | disclosed |
| EP-3313828-A1 | METALLO-BETA-LACTAMASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-05-02 | — | — | EP | disclosed |
| WO-2016210215-A1 | 3-TETRAZOLYL-BENZENE-1,2-DISULFONAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-29 | — | — | WO | disclosed |
| WO-2016206101-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-29 | — | — | WO | disclosed |
| WO-2016210234-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | AZI2, TET3, OXA1L | NCF1 3902/4885PLAU 2199/4885BACE1 2650/4885 |
| US-10221163-B2 | Metallo-beta-lactamase inhibitors | MLX, ZFX, MMP12 | NCF1 1350/4885PLAU 1165/4885BACE1 8/4885 |
| US-20240025919-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | AZI2, TET3, OXA1L | NCF1 3902/4885PLAU 2199/4885BACE1 2650/4885 |
| US-20180179190-A1 | METALLO-BETA-LACTAMASE INHIBITORS | ALPI, GAA, ZFX | NCF1 1250/4885PLAU 934/4885BACE1 20/4885 |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | KRAS, NRAS, HRAS | NCF1 1108/4885PLAU 4870/4885BACE1 2137/4885 |
| US-20180244656-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MLX, ZFX, MMP12 | NCF1 1350/4885PLAU 1165/4885BACE1 8/4885 |
| US-20240368186-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | AZI2, TET3, OXA1L | NCF1 3902/4885PLAU 2199/4885BACE1 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.